Treatment of non-radiographic axial spondyloarthritis: it is only the beginning.

The new nomenclature used in spondyloarthritis (SpA), axial versus peripheral, as proposed by the Assessment of SpondyloArthritis international Society (ASAS) and accepted in 2009, has changed the perspective of ankylosing spondylitis (AS) and other types of spondylarthropathies. 2 The axial type of SpA is subdivided in the (early) nonradiographic type (nr-axial SpA) and the radiographic type, which is equivalent to the diagnosis of AS (according to the modified New York criteria). Instead of debating whether patients with AS do fulfil the grade of radiographic signs of sacroiliitis necessary for the diagnosis AS, the focus of interest has shifted towards the spectre of early detection of inflammation at the MRI of the pelvis and spine. The great advantage of the new nomenclature with an earlier phase of the disease is that the delay in diagnosis of SpA is shortened by years. Now the current research is directed towards the treatment options of this early stage. The first question to be answered in the near future is whether early antitumor necrosis factor (TNF) treatment is effective on clinical symptoms in nr-axial SpA. The second question will be whether treatment in this early phase of the disease will sufficiently suppress inflammation in the long term. Third, and most importantly, the question arises whether this early treatment with anti-TNF has a positive benefit:risk ratio. This early and expensive treatment might diminish symptoms, but it is unclear whether it decreases or even halts the rate of radiographic progression. So far, there is no clear evidence that anti-TNF does delay this process in established AS. In order to answer the first two questions, two interesting studies are published in Annals of Rheumatic Diseases. 10 The ABILITY trial compares the efficacy of adalimumab versus placebo in nr-axial SpA after 12 weeks of treatment. The outcome parameters used in this study were the ASAS 20% and 40% response, and level of inflammation was evaluated by CRP-levels and SPARCC MRI scores of the sacroiliac joints and spine. The results showed a significantly higher number of ASAS40 responders in the adalimumab group (36%) compared with placebo (15%), but the difference between number of responders to adalimumab and placebo is rather small, only 21%. A same small difference (21%) was also observed between ASAS responders after 12 weeks: 52% to adalimumab and 31% to placebo. The relatively high number of responders in the placebo group (31%), is higher compared with most AS studies (between 9% and 21% ASAS 20 responders. This high placebo response rate might be explained by the outcome parameter, the ASAS response, which is based on patient questionnaires for AS and not validated for the nr-axial SpA population, as the authors already mention in their discussion. Part of the response could also be explained by regression to the mean after inclusion at a high level of disease activity. The difference in ASDAS response, though, which also includes the objective parameter CRP, is not very high, but nevertheless, significant (the difference in mean ASDAS change between placebo and adalimumab is −0.7 after 12 weeks). Subanalyses of the patients achieving ASAS 40 response show a trend towards a higher responsiveness in case of elevated CRP, younger age (below 40 years) and higher SPARCC scores at the MRI of the sacroiliac joint (SI) joints, but the number of patients in these subgroups is very small. Moreover, in patients over 40 years of age the percentage of ASAS40 responders is only 17% versus 20% in the placebo and adalimumab groups, respectively, so these patients might not benefit much from this therapy, and larger studies are needed to explore this. By contrast, in patients with a negative MRI and a normal CRP-level at baseline, the response rates between both groups was almost similar, 23% in the adalimumab and 20% in the placebo group. However, the number of patients in these subgroups of ASAS40 responders (figure 2) (5/22 in adalimumab vs 4/20) in placebo) is far too small to draw any conclusions, and this issue should be explored in larger studies. A few interesting points in the patient selection of this study are the exclusion of patients with psoriasis and the relatively high number of patients who also suffered from arthritis (35–52%) compared with other AS populations, in which peripheral arthritis occurs in 25%. Interestingly, 18% of the patients use disease modifying antireumatic drugs (DMARDs) which might influence the joint count and CRP levels (and the ASDAS score as well), because the number of concomitant DMARD users is higher in the MRI-HLA-B27+ subgroup (27%) treated with adalimumab compared with the other groups (table 1). It was not described whether these DMARDs used include sulfasalazine, which does have efficacy in peripheral arthritis and might have a beneficial effect on spinal symptoms as well. Another study which focuses on the treatment of nr-axial SpA with another TNF blocker, etanercept, is a subanalysis of the ESTHER trial. This trial compares the efficacy of etanercept with sulfasalazine in nr-axial SpA and in early AS with a symptom duration not longer than 5 years. All patients in this trial had to have inflammatory lesions at the wholebody MRI. The number of nr-axial SpA patients with a negative MRI were not described in this paper but other studies report a high number, around 70%. 13 The conclusion of the ESTHER trial, involving the whole group of patients (AS and nr-axial spA) was that the efficacy of etanercept was much higher than of sulfasalazine, with an ASAS40 response of 70% in the etanercept compared with 31% in the placebo group. A subanalysis in the ESTHER study was only made of the etanercept (and not the sulfasalazine)-treated patients, which showed equal responsiveness in the 20 AS patients and 20 nr-axial SpA patients, with an ASAS40 response of 75% versus 65%, respectively (table 2). Comparison of both studies in nrradiographic SpA shows a much higher ASAS40 response due to etanercept (ESTHER study) compared with the adalimumab (ABILITY trial). This difference Correspondence to Dr Irene E van der HorstBruinsma, Department of Rheumatology, VU University Medical Center, Room 3A-64, P.O. Box 7057, Amsterdam 1007 MB, The Netherlands; [email protected]